Search results for "glomerulonephritis"

showing 10 items of 45 documents

Increased Goodpasture antigen-binding protein expression induces type IV collagen disorganization and deposit of immunoglobulin A in glomerular basem…

2007

Increased expression of Goodpasture antigen-binding protein (GPBP), a protein that binds and phosphorylates basement membrane collagen, has been associated with immune complex-mediated pathogenesis. However, recent reports have questioned this biological function and proposed that GPBP serves as a cytosolic ceramide transporter (CERTL). Thus, the role of GPBP in vivo remains unknown. New Zealand White (NZW) mice are considered healthy animals although they convey a genetic predisposition for immune complex-mediated glomerulonephritis. Here we show that NZW mice developed age-dependent lupus-prone autoimmune response and immune complex-mediated glomerulonephritis characterized by elevated GP…

Immunoglobulin ACollagen Type IVAgingMice Inbred StrainsMice TransgenicAntigen-Antibody ComplexProtein Serine-Threonine Kinasesurologic and male genital diseasesPathology and Forensic MedicinePathogenesisType IV collagenMiceGlomerulonephritisSpecies SpecificityGlomerular Basement MembranemedicineGoodpasture syndromeAnimalsHumansLupus Erythematosus SystemicAutoantibodiesAutoimmune diseaseBasement membranebiologyGlomerular basement membraneGlomerulonephritismedicine.diseaseImmunoglobulin Amedicine.anatomical_structureImmunologyCancer researchbiology.proteinRegular Articles
researchProduct

Association of redox and inflammation-related biomarkers with prognosis in IgA nephropathy: A prospective observational study.

2022

IgA nephropathy (IGAN) has a variable prognosis. Risk stratification tools are usually based on clinical parameters combined with histologic Oxford-MEST-C score. Circulating redox- and inflammation-related biomarkers may be related to histological changes in IGAN. Therefore, we studied the performance of these biomarkers in predicting the rate of GFR-loss in IGAN.This was an observational prospective study. Fifty-seven stable patients with IGAN were examined at baseline and after a mean observational time of 5.9 ± 1.1 years. The main outcome measure was eGFR-loss per year with predefined groups, stable (1.5 ml/min/1,73 mFifteen patients were in the progressive, 11 in the intermediate, and 3…

InflammationGlomerulonephritis IGABiochemistryAdvanced Oxidation Protein ProductsReceptors Tumor Necrosis Factor Type IPhysiology (medical)Disease ProgressionHumansVDP::Medisinske Fag: 700OsteopontinCysteineProspective StudiesOxidation-ReductionBiomarkersGlomerular Filtration RateFree radical biologymedicine
researchProduct

CD73 Overexpression in Podocytes: A Novel Marker of Podocyte Injury in Human Kidney Disease

2021

The CD73 pathway is an important anti-inflammatory mechanism in various disease settings. Observations in mouse models suggested that CD73 might have a protective role in kidney damage

Male0301 basic medicinePathologyCCR2podocyte030232 urology & nephrologyGene ExpressionKidneyPodocyte0302 clinical medicineFocal segmental glomerulosclerosisMedicineMinimal change diseaseBiology (General)5'-NucleotidaseSpectroscopyAged 80 and overKidneymedicine.diagnostic_testPodocytesGlomerulonephritisGeneral MedicineMiddle AgedComputer Science ApplicationsChemistryProteinuriaminimal change diseasemedicine.anatomical_structureImmunohistochemistryFemaleKidney DiseasesAdultmedicine.medical_specialtyQH301-705.5Receptors CCR2GPI-Linked ProteinsImmunofluorescenceArticleCatalysisInorganic Chemistry03 medical and health sciencesHumansPhysical and Theoretical ChemistryQD1-999Molecular BiologyAgedbusiness.industryOrganic Chemistrymedicine.disease030104 developmental biologyGene Expression RegulationCD73CCR2businessBiomarkersInternational Journal of Molecular Sciences
researchProduct

Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of…

2020

IntroductionAnti-glomerular basement membrane (GBM) antibodies are pathogenic antibodies first detected in renal-limited anti-GBM disease and in Goodpasture disease, the latter characterized by rapidly progressive crescentic glomerulonephritis combined with intra-alveolar hemorrhage. Studies have suggested that anti-GBM antibody positivity may be of interest in lupus nephritis (LN). Moreover, severe anti-GBM vasculitis cases in patients with systemic lupus erythematosus (SLE) have been described in the literature, but few studies have assessed the incidence of anti-GBM antibodies in SLE patients.ObjectiveThe main study objective was to determine if positive anti-GBM antibodies were present …

MaleAnti-Glomerular Basement Membrane Disease[SDV]Life Sciences [q-bio]Lupus nephritisAucunurologic and male genital diseasesSeverity of Illness IndexGastroenterologyanti-glomerular basement membrane antibodies0302 clinical medicinesystemic lupus erythematosusLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineOriginal Researchmedicine.diagnostic_testbiologyanti-GBM glomerulonephritisGlomerular basement membraneIIfMiddle Aged3. Good healthTitermedicine.anatomical_structure[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleAntibodyVasculitisAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialtyImmunology03 medical and health sciencesAntigenInternal medicineanti-GBM antibodiesmedicineHumansAutoantibodiesRetrospective Studies030203 arthritis & rheumatologylupus nephritisbusiness.industryGoodpasture diseasemedicine.diseaseCase-Control StudiesImmunoassaybiology.proteinbusinesslcsh:RC581-607BiomarkersFrontiers in Immunology
researchProduct

Knockout of the KH-Type Splicing Regulatory Protein Drives Glomerulonephritis in MRL-Faslpr Mice

2021

KH-type splicing regulatory protein (KSRP) is an RNA-binding protein that promotes mRNA decay and thereby negatively regulates cytokine expression at the post-transcriptional level. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulated cytokine expression causing multiple organ manifestations

MaleChemokineMice Inbred MRL lprQH301-705.5medicine.medical_treatmentLupus nephritisBiologyKidneyArticleImmune systemsystemic lupus erythematosusimmune system diseasesmedicinecytokineAnimalsCD11a AntigenRNA MessengerKSRPBiology (General)skin and connective tissue diseasesRegulation of gene expressionMice KnockoutSystemic lupus erythematosusFOXP3RNA-Binding ProteinsGlomerulonephritisGeneral Medicinemedicine.diseaseMice Inbred C57BLCytokineCancer researchbiology.proteinTrans-ActivatorsFemaleLymph NodesChemokinesBiomarkersglomerulonephritispost-transcriptional regulationCells
researchProduct

IgE in patients with glomerulonephritis and minimal-change nephrotic syndrome

1979

Serum levels of IgE were studied in 30 children with minimal-change nephrotic syndrome and 32 children with mesangioproliferative glomerulonephritis during different stages of the disease and treatment. In addition, tissue obtained by renal biopsy was investigated by immunofluorescence histology; no deposits of IgE could be found. The serum IgE levels, however, were increased, particularly in patients with minimal-change nephrotic syndrome. It is concluded that IgE does not play a pathogenic role in the development of the renal disease, but that increased IgE levels are an indication of a disturbance of the immune system.

MaleNephrotic SyndromeAdolescentBiopsyNephrosisFluorescent Antibody TechniqueKidneyImmunoglobulin EGlomerulonephritisBiopsymedicineHumansChildKidneybiologymedicine.diagnostic_testbusiness.industryNephrosis LipoidGlomerulonephritisImmunoglobulin Emedicine.diseaseIncreased IgE levelmedicine.anatomical_structureChild PreschoolPediatrics Perinatology and Child HealthImmunologybiology.proteinFemaleRenal biopsybusinessNephrotic syndromeEuropean Journal of Pediatrics
researchProduct

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

2014

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti–complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endotheli…

MaleTime FactorsClinical Trials and ObservationsComplement Membrane Attack Complexurologic and male genital diseasesBiochemistryGlomerulonephritisInside BLOOD Commentaryhemic and lymphatic diseasesMembranoproliferative glomerulonephritisMonoclonalHumanizedComplement ActivationAtypical Hemolytic Uremic SyndromeEndothelial CellHematologyRemission Inductionfood and beveragesHematologyComplement C3Eculizumabmedicine.anatomical_structureFactor HFemalecomplementaHUS eculizumabmedicine.drugMembranoproliferativeHumanmedicine.medical_specialtyEndotheliumMonitoringTime FactorGlomerulonephritis MembranoproliferativeImmunologyBiologyAntibodies Monoclonal HumanizedAntibodiesInternal medicineAtypical hemolytic uremic syndromemedicineHumansPhysiologicMonitoring PhysiologicAdenosine Diphosphate RiboseEndothelial CellsCell Biologymedicine.diseaseComplement systemImmunologyAdenosine Diphosphate Ribose; Antibodies Monoclonal Humanized; Atypical Hemolytic Uremic Syndrome; Complement Activation; Complement C3; Complement Membrane Attack Complex; Endothelial Cells; Female; Glomerulonephritis Membranoproliferative; Hemolytic-Uremic Syndrome; Humans; Male; Remission Induction; Time Factors; Monitoring Physiologic; Hematology; Biochemistry; Cell Biology; ImmunologyHemolytic-Uremic SyndromeComplement membrane attack complexBlood
researchProduct

Clinical course and symptomatic prediagnostic period of patients with Wegener's granulomatosis and microscopic polyangiitis.

1998

The clinical course of 15 patients with Wegener's granulomatosis (WG) and eight patients with microscopic polyangiitis (MPA) from one nephrological clinical center is presented for the period from 1984 to 1993, when testing for antineutrophil cytoplasmic antibodies (ANCA) was gradually introduced into routine clinical practice. We found a high degree of prolonged time periods with symptoms attributable to WG or MPA until the specific diagnosis was made. Nine patients with WG and one patient with MPA had symptomatic prediagnostic periods of more than three years, which extended in one case up to twenty years. In these prediagnostic periods, often even severe flares of vasculitic activity res…

MaleVasculitisPediatricsmedicine.medical_specialtySystemic diseaseTime Factorsmedicine.medical_treatmentRemission SpontaneousSpontaneous remissionCritical Care and Intensive Care MedicineAntibodies Antineutrophil CytoplasmicRenal DialysismedicineRapidly progressive glomerulonephritisHumansCyclophosphamideDialysisAnti-neutrophil cytoplasmic antibodyRetrospective StudiesImmunosuppression Therapybusiness.industryGranulomatosis with PolyangiitisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryNephrologyFemaleMicroscopic polyangiitisComplicationVasculitisbusinessImmunosuppressive AgentsRenal failure
researchProduct

Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome

1999

have been found in patients with end-stage renal disMethods. To investigate a model of nephrotic syndrome in eases, whereas after kidney transplantation, Lp(a) levels the absence of renal failure, we studied a group of 84 children seem to decrease [7‐9]. To explain the increase of Lp(a) in different clinical stages of the disease for a period of five plasma levels in end-stage renal diseases, it has been years. We evaluated the direct relationships between lipoproteins, including Lp(a), and/or plasma albumin and proteinuria. suggested that the kidney might play a role in Lp(a) Results. Lp(a) levels were significantly higher in the subjects metabolism as a catabolic site or by producing some…

Maleglycoproteinmedicine.medical_specialtyNephrotic SyndromeRenal functionchildhood nephrotic syndromeInternal medicineplasma albuminmedicineHumansHypoalbuminemiaChildSerum AlbuminApolipoproteins BProteinuriabiologybusiness.industrylipoproteinAlbuminhypoalbuminuriaGlomerulonephritisCholesterol LDLLipoprotein(a)medicine.diseaseEndocrinologyNephrologyChild PreschoolCreatininebiology.proteinFemalelipids (amino acids peptides and proteins)proteinuriamedicine.symptombusinessNephrotic syndromeLipoprotein(a)LipoproteinKidney International
researchProduct

Development of systemic lupus erythematosus in a patient with selective complete C1q deficiency

1997

A 7-year-old male with recurrent erythematous and desquamated skin lesions and respiratory infections was diagnosed as selective complete C1q deficiency following detailed studies of the complement system. His asymptomatic sister also had selective complete C1q deficiency. During a follow up period of 3 years, his skin lesions persisted, he suffered from recurrent bronchopneumonias and glomerulonephritis developed. Renal function deteriorated with the appearance of anti-DNA antibodies. Renal biopsy was consistent with systemic lupus erythematosus. The patient was treated with immunosuppressive drugs, but died of renal failure. It is postulated that in this patient defective clearance of ant…

Malemedicine.medical_specialtyPathologyBlood Protein DisordersRenal functionDiseaseAsymptomaticFatal OutcomemedicineHumansLupus Erythematosus SystemicPoint MutationRenal InsufficiencyChildLupus erythematosusmedicine.diagnostic_testbusiness.industryComplement C1qGlomerulonephritismedicine.diseaseDermatologyComplement systemPediatrics Perinatology and Child HealthRenal biopsymedicine.symptombusinessMalar rashEuropean Journal of Pediatrics
researchProduct